{"id":"5d59917a8162","type":"article","url":"https://hartvaat.nl/2020/05/26/subcutaan-selatogrel-remt-plaatjesaggregatie-bij-acuut-mi/","title":"Subcutaan selatogrel remt plaatjesaggregatie bij acuut MI","title_en":"Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.03.059","source_url":"https://doi.org/10.1016/j.jacc.2020.03.059","authors":["Peter Sinnaeve","Gregor Fahrni","Dan Schelfaut","Alessandro Spirito","Christian Mueller","Jean-Marie Frenoux","Abdel Hmissi","Corine Bernaud","Mike Ufer","Tiziano Moccetti","Shaul Atar","Marco Valgimigli"],"significance":7,"published":"2020-05-26","source_date":"2020-05-26","image":"","kennis":[],"congress":"","summary_en":"This study of subcutaneous selatogrel showed rapid platelet inhibition in patients with acute MI, testing the concept of a self-administered, rapid-onset P2Y12 inhibitor that patients could use at the onset of chest pain.","created":"2026-07-03T10:28:35Z","updated":"2026-07-03T13:27:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar subcutaan selatogrel (snelwerkende P2Y12-remmer) bij patiënten met acuut MI. Zelftoediening door de patiënt als concept.","abstract_original":"BACKGROUND: Oral P2Y12 receptor antagonists exhibit delayed onset of platelet inhibition in patients with acute myocardial infarction (AMI). Selatogrel is a potent, highly selective, and reversible P2Y12 receptor antagonist with a rapid onset and short duration of action. OBJECTIVES: This study sought to assess inhibition of platelet aggregation following subcutaneous administration of selatogrel in patients with AMI. METHODS: Patients with AMI were randomized to a single subcutaneous dose of selatogrel of 8 or 16 mg. The primary endpoint was response to treatment (P2Y12 reaction units <100; measured by VerifyNow) at 30 min post-dose. Safety was assessed up to 48 h post-injection. RESULTS: Forty-seven patients received selatogrel 8 mg (n = 24) or 16 mg (n = 23) followed by ticagrelor (n = 43) or clopidogrel (n = 1). The proportion of responders 30 min post-dose was 91% (one-sided 97.5% confidence interval [CI]: 80% to 100%) and 96% (97.5% CI: 87% to 100%) with 8 and 16 mg, respectively (p values for responders >85% target; p = 0.142 and p = 0.009, respectively). Response rates were independent from type of AMI presentation, age, or sex. A similar response rate was observed at 15 min (8 mg: 75% [97.5% CI: 58% to 100%]; 16 mg: 91% [97.5% CI: 80% to 100%]), which was sustained at 60 min post-dose (8 mg: 75% [97.5% CI: 58% to 100%]; 16 mg: 96% [97.5% CI: 87% to 100%]). At 15 min, median P2Y12 reaction units was 51 (range: 4 to 208) for 8 mg and 9 (range: 2 to 175) for 16 mg. Selatogrel was well tolerated, without major bleeding complications. CONCLUSIONS: Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-related antiplatelet response. (A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack; NCT03487445, 2018-000765-36 [EudraCT])."}